(Q46231531)

English

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

scientific article published on 21 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

multiple sclerosis

0 references

methylprednisolone

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Per Soelberg Sørensen

7

object named as

P S Sørensen

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

author name string

M Ravnborg

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

K Bendtzen

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

O Christensen

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

P E H Jensen

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

D Hesse

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

M G Tovey

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

publication date

21 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

15

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

323-328

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099476

21 January 2018

Identifiers

10.1177/1352458508099476

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19028832

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46231531&oldid=2100568208"